The assigned homologous single protein target for the DRUGMATRIX assay is Glucocorticoid radioligand binding using the ligand [3H] Dexamethasone. The assay is conducted in vitro with the HeLa S3 cell type and measures the binding properties of the target protein. Specifically, the assay type is classified as a binding assay. Based on the requirements and objectives of this assay, can it be concluded that the molecule exhibits a significant level of efficacy and potency?